Edwards Lifesciences stock rallied Monday on medtech giant Becton Dickinson's plan to buy a key division for $4.2 billion.
BD's (BDX) robust product portfolio raises optimism about the stock.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Edwards Lifesciences (NYSE: EW), today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), a global leader in advanced monitoring solutions, for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.